CORDIS
EU research results

CORDIS

English EN
Heart Failure and Repair

Heart Failure and Repair

Objective

HeartRepair uses the lessons of the embryo to answer the crucial developmental questions regarding heart muscle cell differentiation and develop techniques aimed at harnessing stem cells and or recruiting non-damaged myocardial cells from the infarcted heart to facilitate cardiac repair.
Myocardial infarction is the leading cause of congestive heart failure mainly caused by excessive smoking and bad dietary habits. However, the cause of the subsequent heart failure is simple, massive cardiomyocyte necrosis which fatally perturbs heart function. However, an effective therapeutic approach is simple: replacement of damaged myocardium with viable cardiomyocytes.
Recent advances in the field of stem cell replacement therapies, specifically cardiomyocyte regeneration, gains grace as a realistic alternative for congestive heart repair. Major publications revolve around transplantation trials carried out using either embryonic stem cells or bone marrow derived stem cells. However, Field serious questions the current scientific approach to this research and more importantly if, using current techniques and knowledge, such a goal can realistically ever be reached. Realization of this aim will only be achieved by understanding the underlying principles of cardiac muscle cell formation; the mission statement of HeartRepair.
HeartRepair addresses four R&D themes:
1. Genes for heart repair and plasticity, integrating clinical knowledge based genome sequencing to identify genes involved in heart development;
2. Diversification of cardiac progenitor cells, examining the genetics of cardiac muscle cell formation by exploring the process of cardiomyogenesis and subsequent differentiation;
3. Cell interaction and cardiac reprogramming, exploring the details and signals necessary to facilitate an redirect the cardiac fibroblast cell lineage for repair recruitment;
4. Cardiac rejuvenation, to develop techniques to facilitate and speed repair of damaged, not yet necrotic.

Coordinator

ACADEMIC MEDICAL CENTRE AMSTERDAM

Address

Meibergdreef 15 (K2-119)
Amsterdam

Netherlands

Administrative Contact

Antoon Fm MOORMAN (Professor)

Participants (21)

Sort alphabetically

Expand all

MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Germany

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

INSTITUT PASTEUR

France

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

Italy

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom

UNIVERSIDAD DE JAEN

Spain

MEDIZINISCHE HOCHSCHULE HANNOVER (HANNOVER MEDICAL SCHOOL)

Germany

HUBRECHT LABORATORY

Netherlands

UNIVERSIDAD DE MÁLAGA

Spain

LEIDS UNIVERSITAIR MEDISCH CENTRUM

Netherlands

UNIVERSITAET ZUERICH

Switzerland

CELLARTIS AB

Sweden

JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN

Germany

UNIVERSITÀ DEGLI STUDI DI PADOVA

Italy

NETHERLANDS HEART FOUNDATION

Netherlands

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Spain

FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III

Spain

NATIONALES REGISTER FUER ANGEBORENE HERZFEHLER E.V.

Germany

Project information

Grant agreement ID: 18630

  • Start date

    1 January 2006

  • End date

    30 June 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 12 953 020

  • EU contribution

    € 11 399 998

Coordinated by:

ACADEMIC MEDICAL CENTRE AMSTERDAM

Netherlands